Frances Turregano
Nurse Practitioner · Alexandria, LANPI 1144297763
Payments from drug & device makers
Across 286 payments — averaging $17.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lilly USA, LLC$570
- Novo Nordisk$422
- Amgen$402
- AstraZeneca$306
- GSK$260
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,889100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 87 | $1,392 |
| Lilly USA, LLC | 28 | $570 |
| Novo Nordisk | 29 | $422 |
| Amgen | 23 | $402 |
| AstraZeneca | 11 | $306 |
| GSK | 15 | $260 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $181 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $171 |
| Pfizer | 9 | $149 |
| Sunovion Pharmaceuticals Inc. | 12 | $148 |
| Corcept Therapeutics | 5 | $94 |
| Abbott | 6 | $90 |
| Mylan Specialty L.p. | 4 | $70 |
| Otsuka America Pharmaceutical, Inc. | 3 | $69 |
| Medtronic | 3 | $64 |
| Xeris Pharmaceuticals, Inc. | 3 | $61 |
| Dexcom, Inc. | 3 | $59 |
| Evoke Pharma, Inc. | 2 | $36 |
| Exact Sciences | 2 | $34 |
| Novartis | 2 | $34 |
| Johnson & Johnson | 2 | $29 |
| Eisai Inc. | 2 | $25 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $23 |
| Boehringer Ingelheim | 1 | $22 |
| Averitas Pharma Inc. | 1 | $22 |
| Bausch Health US, LLC | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Genentech USA, Inc. | 2 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Merck | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,889 in reported general payments places this provider in the 90th percentile of 969 nurse practitioner providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 50 | $70,733 |
| EliquisApixaban | 34 | $48,582 |
| MounjaroTirzepatide | 24 | $24,903 |
| OzempicSemaglutide | 14 | $20,557 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $18,465 |
| JanuviaSitagliptin Phosphate | 22 | $18,174 |
| FarxigaDapagliflozin Propanediol | 23 | $17,457 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $15,624 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $13,271 |
| Repatha SureclickEvolocumab | 12 | $7,426 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $4,695 |
| SynthroidLevothyroxine Sodium | 58 | $3,170 |
| Atorvastatin Calcium | 265 | $2,869 |
| Pitavastatin Calcium | 28 | $2,780 |
| Arnuity ElliptaFluticasone Furoate | 13 | $2,663 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $22 | $70,73350 claims |
| PfizerEliquis | $149 | $48,58234 claims |
| MerckJanuvia, Janumet | $14 | $33,79836 claims |
| Lilly USA, LLCMounjaro | $570 | $24,90324 claims |
| Novo NordiskOzempic | $422 | $20,55714 claims |
| AstraZenecaFarxiga | $306 | $17,45723 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $260 | $15,93434 claims |
| AbbVieSynthroid | $1,392 | $3,17058 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 969 nurse practitioner providers in Louisiana.
Other nurse practitioner in Alexandria
- Reghan LittlepageAlexandria$24K
- Kasey GillAlexandria$9K
- Mary GarciaAlexandria$8K
- Karen DeshotelLafayette$264K
- Christopher ManuelKaplan$145K
- Tammy BennettShreveport$99K
- Jessica BordelonHammond$78K
- Teri DugganBossier City$67K
- Matt LandryLafayette$50K
- Cynthia CobbLafayette$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.